{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Neoplasm Metastasis","Liver Neoplasms","Colorectal Liver Metastases"],"disease":["Neoplasm Metastasis","Liver Neoplasms","Colorectal Liver Metastases"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2042657"],"location":["United States"],"study_start_month":["11"],"keyword":["Oxaliplatin","Folfox-B","RhuMAb-VEGF","Anti-VEGF monoclonal antibody","Leucovorin","Eloxatin","Fluorouracil","Bevacizumab","Avastin","5-FU"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Folfox-B Study for Patients With Colorectal Liver Metastases","description":"Objective:\n* To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease.\nPrimary Objective:\n* To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal.\nSecondary Objectives:\n* To evaluate the probability of complete response, partial response or stable disease.\n* To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery).\n* To correlate survival with downstaging and resection based on metastatic colorectal prognostic score.\n* To evaluate the disease-free survival and overall survival.\n* To evaluate the positron emission tomography response rate.\n* To explore correlations of clinical response with telomerase and hTERT expression.","dates":{"creation":"2005-11-15"},"accession":"2042657","cross_references":{"ClinicalTrials___gov":["NCT00508872"]}}